Sutro Biopharma (STRO) Restructuring Costs (2025 - 2026)

Sutro Biopharma (STRO) posted Restructuring Costs of $1.6 million for Q4 2025, down 78.39% sequentially from $7.3 million in Q3 2025.

Analysis

Sutro Biopharma (STRO) Restructuring Costs (2025 - 2026) Analysis & Trends

Sutro Biopharma has reported Restructuring Costs for 1 years, with the latest figure at $1.6 million in Q4 2025.

Quarterly Restructuring Costs changed N/A year-over-year to $1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $26.1 million (changed N/A YoY) and the FY2025 annual result came in at $26.1 million, changed N/A from the prior year.
Restructuring Costs fell to $1.6 million in Q4 2025 per STRO's latest filing, from $7.3 million in the prior quarter.
Over five years, Restructuring Costs peaked at $13.0 million in Q2 2025 and troughed at $1.6 million in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.92 Bn	131.07 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.55 Bn	77.56 Bn	3.93 Bn
3	Argenx Se	63.55 Bn	58.37 Bn	1.37 Bn
4	Moderna	58.26 Bn	53.13 Bn	52.00 Mn
5	Revolution Medicines	44.08 Bn	44.08 Bn	-
6	BeOne Medicines	39.98 Bn	34.89 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.32 Bn	32.01 Bn	992.69 Mn
8	Royalty Pharma	28.42 Bn	27.59 Bn	-
9	Insmed	27.41 Bn	26.25 Bn	358.27 Mn
10	Sutro Biopharma	332.59 Mn	168.25 Mn	-

Historic Data

Download Data